{"id":19370,"date":"2025-08-13T10:14:39","date_gmt":"2025-08-13T10:14:39","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=19370"},"modified":"2025-08-13T10:14:39","modified_gmt":"2025-08-13T10:14:39","slug":"padcev-keytruda-improve-survival-in-bladder-cancer","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/","title":{"rendered":"PADCEV\uff0bKEYTRUDA\u306f\u8180\u80f1\u764c\u306e\u751f\u5b58\u671f\u9593\u3092\u6539\u5584"},"content":{"rendered":"<p><a href=\"https:\/\/www.pfizer.com\/\">\u30d5\u30a1\u30a4\u30b6\u30fc<\/a> \u304a\u3088\u3073 <a href=\"https:\/\/www.astellas.com\/\">\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac<\/a> \u306f\u3001EV-303 \u81e8\u5e8a\u7b2c 3 \u76f8\u8a66\u9a13\uff08KEYNOTE-905 \u8a66\u9a13\uff09\u306e\u826f\u597d\u306a\u7d50\u679c\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002EV-303\u8a66\u9a13\u306f\u3001\u30cd\u30af\u30c1\u30f3-4\u6307\u5411\u6027\u6297\u4f53\u85ac\u7269\u8907\u5408\u4f53\u3067\u3042\u308bPADCEV\u2122\uff08enfortumab vedotin\uff09\u3068PD-1\u963b\u5bb3\u5264\u3067\u3042\u308bKEYTRUDA\u2122\uff08pembrolizumab\uff09\u306e\u4f75\u7528\u7642\u6cd5\u3092\u3001\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u30d9\u30fc\u30b9\u306e\u5316\u5b66\u7642\u6cd5\u304c\u9069\u5fdc\u3068\u306a\u3089\u306a\u3044\u3001\u307e\u305f\u306f\u62d2\u5426\u3055\u308c\u305f\u7b4b\u5c64\u6d78\u6f64\u6027\u8180\u80f1\u304c\u3093\uff08MIBC\uff09\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3001\u30cd\u30aa\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u304a\u3088\u3073\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u6cbb\u7642\uff08\u624b\u8853\u524d\u304a\u3088\u3073\u624b\u8853\u5f8c\uff09\u3068\u3057\u3066\u3001\u73fe\u5728\u306e\u6a19\u6e96\u6cbb\u7642\u3067\u3042\u308b\u624b\u8853\u5358\u72ec\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u3066\u8a55\u4fa1\u3059\u308b\u3082\u306e\u3067\u3059\u3002<\/p>\n<p>\u6709\u52b9\u6027\u306b\u95a2\u3059\u308b\u6700\u521d\u306e\u4e2d\u9593\u89e3\u6790\u3067\u306f\u3001\u672c\u8a66\u9a13\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308b\u7121\u30a4\u30d9\u30f3\u30c8\u751f\u5b58\u671f\u9593\uff08EFS\uff09\u304a\u3088\u3073\u4e3b\u8981\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308b\u5168\u751f\u5b58\u671f\u9593\uff08OS\uff09\u306b\u304a\u3044\u3066\u3001\u30cd\u30aa\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u304a\u3088\u3073\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u306ePADCEV\uff0bKEYTRUDA\u4f75\u7528\u7642\u6cd5\u304c\u624b\u8853\u5358\u72ec\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u3066\u81e8\u5e8a\u7684\u306b\u6709\u610f\u304b\u3064\u7d71\u8a08\u5b66\u7684\u306b\u6709\u610f\u306a\u6539\u5584\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308b\u75c5\u7406\u5b66\u7684\u5b8c\u5168\u594f\u52b9\uff08pCR\uff09\u7387\u3082\u9054\u6210\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p>\u672c\u8a66\u9a13\u3067\u306f\u3001\u30cd\u30aa\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u304a\u3088\u3073\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8KEYTRUDA\u7642\u6cd5\u3068\u624b\u8853\u5358\u72ec\u7642\u6cd5\u306e\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bEFS\u3001OS\u3001pCR\u7387\u306b\u3064\u3044\u3066\u3001\u5f15\u304d\u7d9a\u304d\u6210\u719f\u5ea6\u3092\u8a55\u4fa1\u4e2d\u3067\u3059\u3002PADCEV+KEYTRUDA\u7642\u6cd5\u3068KEYTRUDA\u5358\u5264\u7642\u6cd5\u306e\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u3001\u5404\u6cbb\u7642\u30ec\u30b8\u30e1\u30f3\u306e\u65e2\u77e5\u306e\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3068\u4e00\u81f4\u3057\u3066\u3044\u307e\u3057\u305f\u3002<\/p>\n<h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/nxera-launches-pipeline-for-obesity-weight-management\/\" rel=\"bookmark\">\u30f3\u30af\u30bb\u30e9\u3001\u80a5\u6e80\u75c7\u30fb\u4f53\u91cd\u7ba1\u7406\u7528\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u3092\u767a\u58f2<\/a><\/h4>\n<p>\u8180\u80f1\u304c\u3093\u306f\u4e16\u754c\u30679\u756a\u76ee\u306b\u591a\u3044\u304c\u3093\u3067\u3001\u4e16\u754c\u3067\u6bce\u5e74614,000\u4eba\u4ee5\u4e0a\u306e\u60a3\u8005\u304c\u8a3a\u65ad\u3055\u308c\u3066\u3044\u307e\u3059\u3002ii MIBC\u306f\u5168\u8180\u80f1\u304c\u3093\u60a3\u8005\u306e\u7d0430%\u3092\u5360\u3081\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u672c\u8a66\u9a13\u306e\u7d50\u679c\u306f\u3001\u4eca\u5f8c\u958b\u50ac\u3055\u308c\u308b\u533b\u5b66\u4f1a\u8b70\u3067\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3042\u308a\u3001\u627f\u8a8d\u7533\u8acb\u306e\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u4e16\u754c\u306e\u4fdd\u5065\u5f53\u5c40\u3068\u5354\u8b70\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002\u30cd\u30aa\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u304a\u3088\u3073\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u306ePADCEV\u3068KEYTRUDA\u306e\u4f75\u7528\u7642\u6cd5\u306f\u3001\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u9069\u683c\u306eMIBC\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fEV-304\u7b2c3\u76f8\u81e8\u5e8a\u8a66\u9a13\uff08KEYNOTE-B15\u8a66\u9a13\uff09\u3067\u3082\u8a55\u4fa1\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250812968002\/en\/PADCEV-Plus-KEYTRUDA-Significantly-Improves-Survival-for-Certain-Patients-with-Bladder-Cancer-When-Given-Before-and-After-Surgery\">\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\u30fc<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV\u2122 (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA\u2122 (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. At the first interim efficacy analysis, the trial demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS), the study\u2019s primary endpoint, and overall survival (OS), a key secondary endpoint, with neoadjuvant and [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":19400,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[1960,7046,7047,424,7045],"ppma_author":[205],"class_list":{"0":"post-19370","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-tech","8":"category-international","9":"category-news","10":"category-pharma","11":"tag-astellas-pharma","12":"tag-bladder-cancer","13":"tag-pfizer","14":"tag-pharma","15":"tag-surgical-cystectomy"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PADCEV\u2122 + KEYTRUDA\u2122 Improve Survival in Bladder Cancer<\/title>\n<meta name=\"description\" content=\"Pfizer and Astellas report Phase 3 EV-303 results for PADCEV plus KEYTRUDA in treating bladder cancer patients ineligible for cisplatin.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PADCEV\u2122 + KEYTRUDA\u2122 Improve Survival in Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"Pfizer and Astellas report Phase 3 EV-303 results for PADCEV plus KEYTRUDA in treating bladder cancer patients ineligible for cisplatin.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-13T10:14:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/PADCEV-Plus-KEYTRUDA-Significantly-Improves-Survival-for-Certain-Patients-with-Bladder-Cancer-When-Given-Before-and-After-Surgery.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PADCEV\u2122\uff0bKEYTRUDA\u2122\u304c\u8180\u80f1\u304c\u3093\u306e\u751f\u5b58\u671f\u9593\u3092\u6539\u5584","description":"\u30d5\u30a1\u30a4\u30b6\u30fc\u3068\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac\u3001\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u4e0d\u9069\u5fdc\u306e\u8180\u80f1\u304c\u3093\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fPADCEV\u3068KEYTRUDA\u306e\u7b2c3\u76f8EV-303\u8a66\u9a13\u7d50\u679c\u3092\u767a\u8868.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/","og_locale":"ja_JP","og_type":"article","og_title":"PADCEV\u2122 + KEYTRUDA\u2122 Improve Survival in Bladder Cancer","og_description":"Pfizer and Astellas report Phase 3 EV-303 results for PADCEV plus KEYTRUDA in treating bladder cancer patients ineligible for cisplatin.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/","og_site_name":"itbusinesstoday","article_published_time":"2025-08-13T10:14:39+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/PADCEV-Plus-KEYTRUDA-Significantly-Improves-Survival-for-Certain-Patients-with-Bladder-Cancer-When-Given-Before-and-After-Surgery.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"PADCEV + KEYTRUDA improve Survival in Bladder Cancer","datePublished":"2025-08-13T10:14:39+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/"},"wordCount":316,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/PADCEV-Plus-KEYTRUDA-Significantly-Improves-Survival-for-Certain-Patients-with-Bladder-Cancer-When-Given-Before-and-After-Surgery.webp","keywords":["Astellas Pharma","Bladder Cancer","Pfizer","Pharma","surgical cystectomy"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/","name":"PADCEV\u2122\uff0bKEYTRUDA\u2122\u304c\u8180\u80f1\u304c\u3093\u306e\u751f\u5b58\u671f\u9593\u3092\u6539\u5584","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/PADCEV-Plus-KEYTRUDA-Significantly-Improves-Survival-for-Certain-Patients-with-Bladder-Cancer-When-Given-Before-and-After-Surgery.webp","datePublished":"2025-08-13T10:14:39+00:00","description":"\u30d5\u30a1\u30a4\u30b6\u30fc\u3068\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac\u3001\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u4e0d\u9069\u5fdc\u306e\u8180\u80f1\u304c\u3093\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fPADCEV\u3068KEYTRUDA\u306e\u7b2c3\u76f8EV-303\u8a66\u9a13\u7d50\u679c\u3092\u767a\u8868.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/PADCEV-Plus-KEYTRUDA-Significantly-Improves-Survival-for-Certain-Patients-with-Bladder-Cancer-When-Given-Before-and-After-Surgery.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/08\/PADCEV-Plus-KEYTRUDA-Significantly-Improves-Survival-for-Certain-Patients-with-Bladder-Cancer-When-Given-Before-and-After-Surgery.webp","width":1200,"height":800,"caption":"PADCEV"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/padcev-keytruda-improve-survival-in-bladder-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"PADCEV + KEYTRUDA improve Survival in Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/19370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=19370"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/19370\/revisions"}],"predecessor-version":[{"id":19371,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/19370\/revisions\/19371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/19400"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=19370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=19370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=19370"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=19370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}